ArticleBioactive materials2026
Biomimetic universal CAR-mesenchymal stem cell nanohybrids for anti-tumor therapy.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Stage-specific biomimetic nanoparticles reprogram osteoblast-adipocyte equilibrium for targeted osteoporosis therapy.Bioactive materials · 2026Article
- Advances of Cell Membrane-Coated Nanotechnology and Membrane Vesicles in Intestinal Targeted Drug Delivery Systems.Pharmaceutics · 2026Review
- Biomimetic nanovesicles decorated with chemotactic and target membrane proteins for lupus nephritis treatment.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current autologous chimeric antigen receptor (CAR)-T cell therapies are hindered by significant challenges, including the lack of off-the-shelf availability, prolonged manufacturing timelines, and inconsistent product quality, which limit their broader application and clinical efficacy. To address these limitations, we developed an innovative universal CAR nanoplatform by engineering mesenchymal stem cells (MSCs) with CAR and integrating them with multifunctional hybrid nanoparticles. This platform leverages the intrinsic tumor-homing properties of MSCs and the specificity of CAR to achieve precise tumor targeting and eradication. Specifically, we targeted C-type lectin-like molecule-1 (CLL-1), a marker specifically expressed on acute myeloid leukemia (AML) blast cells and leukemia stem cells (LSCs), to create an anti-CLL-1 CAR-MSC (aCLL-1 CAR-MSC) nanoplatform for AML therapy. To further enhance therapeutic efficacy, we incorporated biomimetic nanotechnology for the targeted delivery of shikonin (SK) nanohybrids, which amplify SK-induced immunogenic cell death in tumor. This dual approach not only improved anti-AML activity but also extended the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.